Why Do My Eyes Burn Since Starting Glaucoma Drops?

Quick Answer: Your glaucoma drops likely cause the burning, because the preservative benzalkonium chloride (BAK) damages your tear film. Treating both together, often with preservative-free drops, improves comfort, test accuracy and adherence.

Written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist. She trained in both cornea and glaucoma at AIIMS, New Delhi, for three years. Last reviewed: [date].

If your eyes burn, sting or feel gritty on glaucoma drops, you are not imagining it. This is common. Most patients assume it is part of the package, so they stay quiet.

Burning does not mean your glaucoma is getting worse. It usually means your ocular surface needs care. Do not stop or change your glaucoma drops without speaking to your doctor. Missed drops can let glaucoma progress without any symptoms.

Key Takeaways on Glaucoma and Dry Eyes

  • Dry eye affects 40 to 60 percent of people on long-term glaucoma drops.
  • Preservatives such as BAK often cause the burning.
  • Dry eye can distort pressure readings, OCT scans and visual fields.
  • Preservative-free drops, laser and surface care can restore comfort.
  • Never stop your glaucoma drops without your doctor’s advice.

How Common Is Dry Eye in Glaucoma?

Studies show that 40 to 60 percent of glaucoma patients also have dry eye disease [1, 2]. The two conditions share risk factors, such as older age and menopause. They are still separate diseases.

Why Do Glaucoma Drops Cause Dry Eye?

1. The preservative (BAK)

Most glaucoma drops contain BAK. BAK keeps the bottle sterile. It also harms the surface of your eye [3].

BAK breaks up the tear film. It damages goblet cells, which make the mucus layer of your tears. It also triggers chronic inflammation.

Many patients use two or three drops a day. That means four to six BAK exposures daily, for years. The damage builds slowly. This is an expected effect of long-term BAK use. It is not rare.

2. Dry eye you already had

Older age, menopause and autoimmune disease raise the risk of dry eye. Many patients reach a glaucoma diagnosis with a weak surface already. Added BAK speeds up the damage.

3. Oil gland problems

Most dry eye in glaucoma patients is evaporative. The meibomian glands in your lid margins stop making enough good oil. Your tears then dry out too fast.

4. Screen time

You blink less on screens. Your tears evaporate faster, and drops sting more. Read more on why vision blurs after screen use.


What Does Your Symptom Mean?

SymptomLikely causeWhen to worry
Burning or stinging right after a dropBAK irritation on a dry surfaceRedness, swelling or pain after every drop. This may signal an allergy to a drop.
Gritty, sandy feeling by eveningEvaporative dry eye, oil gland problemsLubricating drops do not help.
Watery eyesIrritated surface triggers reflex tearingTearing comes with discharge or a red, painful eye.
Blur that clears with blinkingUnstable tear filmBlur does not clear, or vision drops suddenly.
Dull ache, halos and rednessNot dry eye. Eye pressure may be rising.Get care the same day.
You skip drops because they hurtDrop discomfortTell your doctor now. Missed drops let glaucoma progress silently.

Why Does the Glaucoma and Dry Eyes Overlap Matter?

  • Adherence. Pain makes patients skip drops. Uncontrolled pressure then damages the optic nerve. Treating dry eye protects your drop routine.
  • Test accuracy. An unstable tear film blurs visual field tests. It can create false dips that mimic progression. It can also lower OCT scan quality and make pressure readings less reliable.
  • Surgery planning. Years of surface inflammation can leave the conjunctiva less healthy for filtering surgery.
  • Quality of life. Chronic burning, light sensitivity and fluctuating vision are not inevitable. See more on quality of life in glaucoma.

How My Cornea and Glaucoma Superspeciality Training Affects my Clinical Decisions

I spent three years as a Senior Research Associate in the Cornea and Glaucoma Services at AIIMS, New Delhi. I managed complex tertiary referral patients with glaucoma and ocular surface disease.

That training changed how I see a glaucoma patient. I look at the surface first, not only the optic nerve. I count every drop, every bottle and every preservative. I ask whether you skip drops because they hurt.

Successful glaucoma care is not only about lowering eye pressure. It means protecting vision long-term while keeping the surface healthy enough to stay on treatment for life.


How Do I Assess This in the Clinic?

At my Gurgaon clinic, a glaucoma review for surface complaints includes:

  • Tear breakup time (TBUT): It measures how fast your tear film breaks after a blink.
  • Surface staining: Fluorescein and lissamine green dyes show damaged cells on the cornea and conjunctiva.
  • Meibomian gland check: I look for blocked or weak oil glands.
  • OSDI questionnaire: It captures symptoms the slit lamp cannot show.
  • Drop review: I check which drops you use, how many, and how often.

What Are the Treatment Options?

1. Switch to preservative-free drops

This is often the most helpful step. Preservative-free drops lower pressure as well as preserved drops do. They skip the surface toxicity. Preservative-free options exist for prostaglandin analogues, beta-blockers, carbonic anhydrase inhibitors and some combinations. The TFOS DEWS II report on drug-induced dry eye supports this approach [4].

Availability and cost vary. Ask your specialist which options suit you. Read the complete guide to glaucoma eye drops.

2. Use fixed-dose combination drops

One bottle with two medicines means fewer drops and fewer preservative exposures. For many patients, this is a practical first step.

3. Treat the dry eye directly

  • Artificial tears: Choose preservative-free tears. Use them regularly through the day.
  • Warm compresses and lid hygiene: They improve the quality of your oil layer.
  • Omega-3: Read the evidence on omega-3 and dry eye.
  • Anti-inflammatory drops: Topical cyclosporine, or lifitegrast where available, calms the inflammation that keeps dry eye going.
  • Punctal plugs: Tiny plugs keep your natural tears on the eye longer.

4. Use laser or surgery to cut your drop load

Some patients can reduce or stop drops. Selective laser trabeculoplasty (SLT) lowers pressure without drops. For advanced disease, minimally invasive glaucoma surgery (MIGS) or trabeculectomy can cut drop burden. See also laser to avoid eye drops.


What Doctors Often Miss

  • Irritation gets blamed on glaucoma progression. More often, it comes from the surface.
  • Tests run through a dry surface. A visual field done through an unstable tear film is not a trustworthy test. I prefer to stabilise the surface first, or treat both together.
  • Nobody adds up the total BAK load across all your bottles.
  • Nobody asks about skipped drops. Patients rarely volunteer it.

Can Dry Eye Cause Glaucoma?

No. Dry eye does not cause glaucoma. The two diseases have different mechanisms. Both become more common with age, and chronic inflammation may play a role in each. Researchers are still studying that link.

A Warning About Steroid Eye Drops

In India, pharmacies sometimes sell steroid eye drops without a prescription. They ease redness and irritation fast, so patients keep using them.

Long-term, unsupervised steroid drops can raise eye pressure and cause steroid-induced glaucoma. This can permanently damage the optic nerve. Steroids also speed up cataracts and raise infection risk.

Never use steroid drops for persistent dry eye without an ophthalmologist’s advice.


When to See a Doctor

See a Doctor Urgently (Same Day)

  • Sudden loss or drop in vision
  • Severe eye pain, especially with redness, halos or nausea
  • A white spot on the cornea, or pus, especially in contact lens wearers
  • Chemical splash or eye injury
  • Severe light sensitivity with a red, painful eye

See a Doctor (Book a Visit)

  • Burning or grittiness that lasts more than a few days on your drops
  • You skip or shorten your drops because they hurt
  • You use two or more glaucoma drops
  • You need lubricating drops many times a day
  • Your visual field or OCT results vary from visit to visit
  • You use steroid drops without advice

What This Means for You

Burning on glaucoma drops is common, and you can fix it. Do not accept it as normal. Do not stop your drops on your own.

Tell your doctor:

  • Which symptoms bother you most (burning, grittiness, blur, light sensitivity)
  • Whether symptoms get worse after drops or at certain times of day
  • Whether you have ever skipped or reduced drops because of discomfort
  • How many hours a day you spend on screens

This does not make you a difficult patient. It makes your care more precise.


Frequently Asked Questions

Can glaucoma drops cause dry eye?

Yes. Most glaucoma drops contain BAK. Over time, BAK causes inflammation, goblet cell loss and dry eye. Preservative-free drops often bring relief.

Can I use artificial tears with my glaucoma drops?

Yes, and many patients should. Wait at least five minutes between different drops, so one does not wash out the other. Ask your doctor to confirm the best order for your drops.

Are preservative-free glaucoma drops as effective?

Yes. The active medicine is the same. The preservative only keeps a multi-dose bottle sterile. Preservative-free drops come in single-dose units.

Can dry eye affect my glaucoma test results?

Yes. An unstable tear film can distort pressure readings, OCT scans and visual fields. That is why I assess the ocular surface in glaucoma care.

Can I use laser if my eyes cannot tolerate drops?

Often, yes. SLT can lower pressure and reduce your need for drops. If drop toxicity is severe, your doctor may also discuss surgery.


Book a Consultation

Burning, irritation or fluctuating vision on glaucoma treatment has options beyond more lubricating drops. A full assessment can tell whether you have dry eye, preservative toxicity, oil gland dysfunction or another surface problem. Then I tailor treatment to your glaucoma and your comfort.

Whether you need a second opinion, have drops that no longer feel comfortable, or want to explore preservative-free drops, laser or surgery, I can help.

Book an Appointment:

📍 Gurgaon 📞 +91 88826 38735 | 🌐 Contact Us | Second Opinion Form for teleconsults

Glaucoma (L.I.F.T.S.™): L.I.F.T.S.™ checks records over time, re-confirms the diagnosis, measures progression speed, sets target pressure, then recommends observe, refine or escalate.

Dry eye (C.L.E.A.R.™): C.L.E.A.R.™ finds your dry eye subtype, maps oil glands, audits drops and medicines, measures inflammation, then builds a root-cause plan.


This page is a part of the Glaucoma Hub. you may want to read about Glaucoma Progression, , and Risk Stratification in Glaucoma. Other articles of interest could be Advanced Glaucoma Care in Gurgaon, What Good Glaucoma Care Actually Optimises For, What Happens If Glaucoma Is Left Untreated?, More Glaucoma Eye Drops is Not Better Glaucoma Care, 5 Mistakes Patients Make in Glaucoma Care and Do You Really Need Treatment for Glaucoma?

This article is part of the Dry Eye Hub. Please also read Basics of Dry Eye, Dry Eye Second Opinion and Dry Eye: A Chronic Disease. Why Vision Becomes Blurred After Reading or Screen Use, Why Dry Eye Symptoms and Tests Don’t Match, and Why Are Your Dry Eye Drops Not Working may also help you understand your problem better.

You may want to read How to remember your glaucoma medication, Tips and tricks on how to use your eye drops, Whether refrigerating eye drops helps, How to manage side effects of glaucoma drops, Why my dry eye drops are not working, How to reduce glaucoma drops, Glaucoma drops not working, and Glaucoma progressing despite eye drops.

You may also want to learn how to put eyedrops here.


About the Author

TThis article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

Dr Bhartiya has published peer-reviewed research onglaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes. She is also a committed patient advocate and mainstream medical columnist, translating complex ophthalmic evidence into actionable public health insights across leading national platforms including NDTV and OnlyMyHealth

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1600+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID | Github | Wikidata

📋Upload your reports for a structured review.| 🌐 Contact Us| 📞 +91 88826 38735

⭐ Helped by this article? Leave a Google review — it helps other patients find reliable eye care.

Last Reviewed: October 2026


Read More

Basics of Dry Eye, Dry Eye Second Opinion, Dry Eye: A Chronic Disease

Why Do Women Get Dry Eye More Often? Menopause and Dry Eye

Dry Eyes: Natural Remedies, Dry Eyes: Tips to Soothe Sore Eyes

Why Dry Eye Is Worse in Air Conditioning and on Flights

Screen Fatigue, Why Vision Becomes Blurred After Reading or Screen Use,

Why Your Eyes Water Constantly, Omega-3 and Dry Eye, Why Are Your Dry Eye Drops Not Working

Glaucoma Eye Drops: The Complete Guide, Laser or Eye Drops for Glaucoma

Managing Glaucoma Eye Drop Side Effects, Which Is the Best Eyedrop for Glaucoma?

Why Do I Need So Many Glaucoma Eye Drops?

Ocular GVHD: Eye Problems After BMT

Ocular GVHD (Graft-Versus-Host Disease) is an immune-mediated condition that develops after a bone marrow or stem cell transplant. Donor immune cells attack the tear glands and eye surface, causing dry eyes, burning, redness, and light sensitivity. Early specialist evaluation and treatment protect the eye surface and preserve vision long-term.


Ocular GVHD affects your eyes after a bone marrow or stem cell transplant. Donor immune cells target your tear glands and corneal surface. The condition can appear weeks, months, or even years after transplant. Early identification changes outcomes significantly.

This condition sits at the intersection of haematology and ophthalmology. Your transplant team and your eye doctor need to work together. Regular eye review is part of post-transplant care, not an optional extra.


What Is Ocular GVHD?

Graft-Versus-Host Disease (GVHD) is an immune-mediated inflammatory reaction. It occurs when donor immune cells recognise the recipient’s tissues as foreign and attack them. Several organs can be affected, including the skin, liver, gut, and eyes.

The eye is more commonly affected in chronic GVHD, but acute GVHD can also involve the ocular surface. When the eyes are involved, the condition is called Ocular GVHD.


What Are the Symptoms of Ocular GVHD?

Symptoms range from mild to severe. They include one or more of the following:

  • Dry eyes and a persistent gritty sensation
  • Burning and irritation
  • Redness
  • Excessive watering and tearing
  • Light sensitivity
  • Blurred or fluctuating vision

In children, obvious complaints are often absent. Parents may notice excessive eye rubbing, light sensitivity, or reluctance to open the eyes in bright light.

Do not dismiss vague symptoms such as discomfort, scratchiness, or eye fatigue. These can be early signs of ocular GVHD. Your transplant surgeon may request an eye evaluation even when you have no symptoms at all.


How Is Ocular GVHD Diagnosed?

A complete eye examination is the starting point. This includes visual acuity testing, refraction, slit-lamp examination, and tear film assessment.

Your eye doctor will also perform specific tests to evaluate the ocular surface. These include the Schirmer’s test, and staining of the cornea with fluorescein and/or Rose Bengal dyes. These tests assess tear production and identify surface damage not visible to the naked eye.


How Is Ocular GVHD Treated?

Management focuses on controlling dryness, reducing inflammation, preventing infection, and protecting the cornea from scarring.

Systemic drugs given by your bone marrow transplant team for the rest of the body often do not adequately treat the eyes. Your eye doctor will likely recommend one or more of the following:

  • Lubricating eye drops to improve comfort and reduce corneal damage
  • Steroid eye drops to control inflammation and prevent scarring
  • Antibiotic eye drops to prevent or treat secondary infection
  • Autologous serum eye drops to support healing of the ocular surface
  • Cyclosporine eye drops to reduce the immune-mediated reaction

Treatment is adjusted over time based on disease activity and symptom burden. This is a condition that needs long-term follow-up, not a single course of treatment.


How is Ocular GVHD Classified?

Acute ocular GVHD develops during or soon after systemic acute GVHD and is characterized by sudden inflammation, redness, pain, tearing, photophobia, and conjunctival involvement.

Chronic ocular GVHD is a long-term immune-mediated disease that typically presents with persistent dry eye, burning, grittiness, fluctuating vision, meibomian gland dysfunction, and progressive ocular surface damage.

Acute-on-chronic ocular GVHD occurs when a patient with established chronic ocular GVHD experiences a sudden inflammatory flare, causing a rapid worsening of symptoms such as redness, pain, light sensitivity, and ocular surface inflammation on top of their baseline chronic dry eye disease.


Who Is Most at Risk?

Anyone who has undergone a bone marrow or stem cell transplant can develop ocular GVHD. Risk is higher in:

  • Patients with chronic GVHD affecting other organs
  • Patients on prolonged immunosuppression
  • Those with a history of acute GVHD

Children who have had transplants are a particularly vulnerable group. Symptoms may be subtle. Eye problems can quietly affect reading, school performance, and daily comfort without an obvious complaint from the child.


When to See a Specialist

See an eye specialist promptly if any of the following apply.

You or your child has had a bone marrow or stem cell transplant, and eye symptoms have appeared at any point after — not only in the early weeks.

Symptoms are present but mild. Mild ocular GVHD does not stay mild without treatment. Surface damage accumulates quietly.

Your transplant team has not yet arranged an ophthalmic review. Ask for one. It should be part of standard post-transplant follow-up.

Vision feels “off” even though a recent check showed normal acuity. Tear film instability affects functional vision. Standard acuity testing does not capture it.

You have been given lubricants but the symptoms persist. This is a signal for specialist evaluation, not a reason to try a different brand of drops.

What Doctors Sometimes Miss

Ocular GVHD is underdiagnosed. Several patterns come up repeatedly in practice.

Symptoms labelled as “just dry eyes.” Post-transplant dryness is not routine dry eye. The mechanism is different, the severity is higher, and the risk of corneal scarring is real. It needs specialist evaluation, not over-the-counter drops.

Children who don’t complain. A child who rubs their eyes, squints, or avoids reading is not always being difficult. These are ocular surface symptoms. Parents and transplant teams both need to watch for them.

The quiet chronic phase. Acute GVHD gets attention. Chronic ocular GVHD can smoulder for months with low-grade symptoms. Vision may remain measurably normal while the surface continues to deteriorate. Symptom absence does not mean the eye is safe.

Delayed referral from transplant teams. Eye review is sometimes requested only after symptoms become severe. Baseline ophthalmic evaluation before or shortly after transplant is better practice. Earlier review means earlier intervention.


Ocular GVHD: Symptoms, Causes, and When to Worry

SymptomWhat It MeansWhen to Worry
Dryness and grittinessTear gland damage from donor immune cellsIf persistent or worsening despite lubricants
Burning and irritationOcular surface inflammationIf affecting daily activities, reading, or sleep
RednessConjunctival involvementIf sudden, severe, or accompanied by pain
Light sensitivityCorneal surface damageIf debilitating or new after a settled period
Blurred or fluctuating visionTear film instability or corneal changesAlways warrants prompt specialist review
Eye rubbing in childrenMay be the only visible signIf post-transplant, refer early — do not wait
Watering and tearingReflex response to surface drynessIf combined with other symptoms

FAQs

Can ocular GVHD occur without dry eye symptoms?

Yes. Some patients present with redness, light sensitivity, or blurred vision rather than classic dryness. In children, the only sign may be eye rubbing or reluctance to be in bright light. A specialist examination is more reliable than symptom-based self-assessment.

Does ocular GVHD go away on its own?

Occasionally it settles with time, but many patients need long-term treatment. Stopping treatment early often leads to flare-ups. Your eye doctor will guide when and how to taper any medications.

Can both eyes be affected?

Yes. Ocular GVHD typically affects both eyes, though one side may be more symptomatic than the other.

Is teleconsultation available for ocular GVHD follow-up?

Yes. If you live outside Gurgaon or are unable to travel, teleconsultation is available to support ongoing management in partnership with your local eye doctor.


This page is part of the Dry Eye Disease hub. Read about our full approach to GVHD, dry eyes, and children’s eye care. Please also read the Pediatric Eye Care hub.

Here’s another heartening patient story: A young boy and his love for trucks, and Chronic GVHD and Success Stories.


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google

Read a patient story:

Ocular GVHD in Children

Chronic GVHD and Success Stories

Ocular Graft Versus Host Disease in Children

Ocular GVHD (Graft-versus-Host Disease) can cause severe dry eyes, burning, fluctuating vision, light sensitivity, and damage to the eye surface after a bone marrow or stem cell transplant. Early diagnosis and long-term eye care may help protect comfort, vision, and quality of life.

Managing these cases requires specialised corneal expertise, strict protective isolation compliance, and a deeply trauma-informed approach to pediatric clinical examination. Scientific precision alone is not enough — the child must feel safe enough to let you in.


Beyond the Sterile Barrier: Pediatric Ocular Graft-Versus-Host Disease

There are moments in a pediatric ophthalmologist’s career that anchor you for life.

During my time at Fortis, I cared for a tiny boy fighting for his life after a bone marrow transplant. Severe, acute Ocular GVHD had left his corneas damaged, covered in countless microscopic raw spots — Superficial Punctate Keratitis — causing blinding pain and extreme light sensitivity. He lived in the ICU, unable to open his eyes, afraid of every sound.

His immune system was almost non-existent. Anyone entering his space had to be covered head to toe in sterile gowns and masks. He could not see my face. He was terrified. Some days, he was too weak to cry.

To help him recognise me without triggering fear, I started a routine. Every time I entered his isolation pod, I whistled softly. He learned quickly. The whistle meant safety. No needles. It meant the person coming was not going to hurt him.

I would apply a careful drop of anaesthetic to numb the intense surface pain just enough to let me examine his corneas and adjust his treatment. And I kept talking. Through every protocol, every follow-up, every barrier-gowned visit, a bond formed between us.

His parents would quietly hold him. Silently, patiently, with all the love in the world.

Can GVHD be cured?

That was the only question they asked. For the pain to go away. I would say yes, he will be fine. And pray, silently.

And then one day, instead of crying, he started talking. About trucks, and JCBs and construction. All of five. And bright. And happy. Like any other five year old.

The drops continued, but he was now walking into my OPD, showing off his toys, his jeans, his shoes which have red and blue lights. And one day, we didn’t need any medication at all.

Today, he is completely cured — a bright, healthy boy, a handful and a half. Goes to big school. And to Goa with his grandparents. Collects toy trucks, especially likes yellow ones.

When he walks into my clinic, he does not see masks or sterile gowns. He sees a friend. He spots me from across the waiting room and runs full tilt into my arms. And talks till my ears hurt. And my face hurts. From smiling so much.

His parents recently told me that when they return to his BMT hospital for follow-ups, he looked up at the first floor where my old OPD used to be and insisted: “Let’s go meet Dr Shibal.” They had to remind him gently that I have moved. When he visited me at Marengo Asia after that, he looked around the new clinic and said, with complete satisfaction: “Dr Shibal, you always own the first floor.”

He is entirely right. Just like he owns my entire heart.

PS: Two of his classmates have come to me to get their glasses checked. Apparently he tells everyone about “My doctor” who has a hundred toffees. My little advertising blitzkreig he is 🙂


FAQs

What is Ocular GVHD in children, and what are the symptoms?

Ocular GVHD occurs when donor immune cells after a bone marrow transplant attack the recipient’s lacrimal glands and corneal surface. In children, symptoms include severe eye pain, redness, a gritty sensation, extreme light sensitivity, and refusal to open the eyes due to corneal surface damage. Early specialist intervention is critical to prevent permanent scarring.

What are the most common symptoms of ocular GVHD in adults?

Symptoms may include dry eyes, burning, redness, watering, irritation, light sensitivity, fluctuating vision, eye fatigue, and a feeling of grit or sand in the eyes.

Can ocular GVHD affect vision permanently?

If untreated, ocular GVHD can lead to chronic surface damage, discomfort, and vision changes. Early treatment and regular follow-up may reduce the risk of long-term complications.

How is ocular GVHD diagnosed?

Diagnosis is based on symptoms, eye examination, tear film assessment, evaluation of the eye surface, and correlation with transplant history and systemic GVHD status.

What treatments are available for ocular GVHD?

Treatment may include preservative-free lubricants, medicines to reduce inflammation, tear conservation strategies, ocular surface support, and long-term monitoring depending on severity.

How is severe pain and photophobia managed in post-transplant pediatric patients?

Management is multi-layered and highly specialised. It includes preservative-free lubricants, autologous serum eye drops, therapeutic scleral or bandage contact lenses, and targeted topical immunomodulators. During acute flares, topical anaesthetics are used carefully during examination by the specialist — never for unsupervised home use — to allow assessment without causing further distress to the child.


This article is a part of the Paediatric Ophthalmology Hub. Read about our full approach to children’s ophthalmology. Please also read Children’s Eye Care, Nutrition, Are Children’s Eyes More Vulnerable, Lazy Eye, and Myopia Prevention in Children. Eye Care Tips for Screen Use, and 7 Ways to Take Care of Your Child’s Eye Health also may be of interest. You may want to see some eye care tips for children here, here, and here.

Please also read Dry Eye Disease

Here’s another heartening patient story: the young girl who is now a doctor herself!


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

1500+ Five Star Patient Reviews Google Business Profile

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read her research on PubMed | Google Scholar | ResearchGate | ORCID

Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735

Leave a review on Google


Dry Eye Is Not Just Dryness: Managing It as a Chronic Condition

Dry eye disease is a chronic condition caused by an unstable or insufficient tear film. It does not go away with occasional lubricating drops. Left unmanaged, it causes progressive surface damage, worsening discomfort, and, in some cases, permanent corneal scarring. Long-term management, not short-term relief, is the correct approach, says Dr Shibal Bhartiya.

The C.L.E.A.R.™ Dry Eye Second Opinion Framework, devised by Dr Shibal Bhartiya, is a structured, evidence-based approach that identifies the underlying causes of dry eye disease to guide personalised, root-cause treatment.

Dry eye is one of the most common eye conditions seen in clinical practice. Most patients manage it with over-the-counter drops and expect it to resolve. It rarely does.

Dry eye disease is a multifactorial condition of the ocular surface. The tear film is complex. When it breaks down, the result is inflammation, epithelial damage, and a cycle that perpetuates itself without targeted treatment.

Dry eye disease is a chronic condition that usually cannot be cured permanently, but it can be controlled successfully. Most patients improve with:

  • consistent treatment
  • eyelid hygiene
  • preservative-free artificial tears
  • treatment of meibomian gland dysfunction
  • regular follow-up

The goal is long-term comfort, not temporary relief. Understanding dry eye as a chronic disease changes how patients manage it, and how much vision and comfort they can preserve over time.

Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.


What Is Dry Eye Disease?

Dry eye disease (DED) is defined by the TFOS DEWS II report as a multifactorial disease of the ocular surface. It involves loss of tear film stability and is accompanied by symptoms and signs of varying severity.

The tear film has three layers: a mucin layer anchoring tears to the eye surface, an aqueous (watery) layer providing nutrients and oxygen, and a lipid (or oil) layer produced by the meibomian glands that prevents evaporation. A problem in any one layer causes disease.


Two Main Types of Dry Eye

Aqueous Deficient Dry Eye

This type involves insufficient tear production. The lacrimal gland does not produce enough aqueous fluid. It is common in post-menopausal women, patients with Sjogren’s syndrome, and those on antihistamines, antidepressants, or blood pressure medications.

Evaporative Dry Eye

This is the more common type, accounting for roughly 85 percent of all dry eye cases. Meibomian gland dysfunction (MGD) is the primary cause. Blocked or abnormal meibomian glands fail to secrete a healthy lipid layer, and tears evaporate too quickly.

Many patients have both types simultaneously. Treatment must address the dominant mechanism.

FeatureAqueous Deficient DEDEvaporative DED
Primary causeReduced lacrimal gland outputMeibomian gland dysfunction
Proportion of casesApproximately 15%Approximately 85%
Key risk factorsSjogren’s, medications, ageScreen use, blepharitis, rosacea
Tear break-up timeReducedVery short (under 5 seconds)
Treatment focusTear supplementationLid hygiene, heat, omega-3
Inflammation presentOften yesYes, secondary

Why Dry Eye Becomes Chronic

The tear film and ocular surface exist in a feedback loop. When the tear film is unstable, the surface desiccates. This triggers inflammation. Inflammation damages goblet cells and lacrimal tissue. Damaged tissue produces less stable tears. The cycle continues.

Without breaking this cycle, not just lubricating the surface, dry eye worsens over months and years. This is why patients who only use drops often find their symptoms returning or intensifying.

Chronic untreated dry eye can cause corneal epithelial breakdown, punctate keratitis, subepithelial scarring, and, in severe cases, corneal ulcers. These are not trivial outcomes.

Please read Can Blepharitis or Rosaceae Cause Dry Eyes?, and Do You Need to Splash Water in Your Eyes to Clean Them? 


Risk Factors That Drive Progression

  • Screen use of more than four hours daily reduces blink rate and increases evaporation.
  • Contact lens wear disrupts the tear film and accelerates meibomian gland dropout.
  • Hormonal changes — especially menopause — reduce lacrimal and meibomian secretions.
  • Systemic medications including antihistamines, SSRIs, diuretics, and isotretinoin reduce tear production.
  • Autoimmune conditions such as rheumatoid arthritis, lupus, and thyroid disease affect the lacrimal gland.
  • Rosacea is a strong risk factor for meibomian gland dysfunction and is frequently undiagnosed.
  • Air conditioning, low humidity, and air travel accelerate tear evaporation.
  • Prior LASIK or refractive surgery causes corneal nerve damage and temporarily reduces reflex tearing.

How Dry Eye Is Diagnosed

Diagnosis requires more than a symptom questionnaire. A structured assessment includes the OSDI (Ocular Surface Disease Index) score, tear break-up time (TBUT), Schirmer’s test, corneal and conjunctival staining with fluorescein and lissamine green, and meibomian gland evaluation.

Meibography — infrared imaging of the meibomian glands — shows the degree of gland dropout and guides treatment intensity. Patients with significant gland loss need early and aggressive intervention to preserve remaining function.

Tear osmolarity testing measures the salt concentration of tears. Elevated osmolarity confirms tear film instability and is useful for monitoring treatment response objectively.

Diagnostic TestWhat It MeasuresClinical Significance
TBUT (tear break-up time)Tear film stabilityUnder 10 seconds is abnormal
Schirmer’s testAqueous tear productionUnder 10 mm in 5 min is reduced
Corneal fluorescein stainingEpithelial surface damageConfirms active disease severity
MeibographyMeibomian gland structure and dropoutGuides long-term prognosis
Tear osmolarityTear salt concentrationOver 308 mOsm/L confirms DED
OSDI scoreSymptom burdenTracks treatment response over time

If screen-related eye pain is affecting your work or daily life, a full assessment takes under an hour. Dr Shibal Bhartiya — dry eye specialist and glaucoma specialist in Gurgaon — will identify whether this is screen strain or something that needs treatment.

The C.L.E.A.R.™ Dry Eye Second Opinion Framework, devised by Dr Bhartiya, is a structured, evidence-based approach to diagnosing the underlying causes of dry eye disease. Rather than simply treating symptoms, it identifies the specific mechanisms driving your condition to enable personalised treatment.

📍 Gurgaon 📞 +91 88826 38735 | 🌐 Contact Us | Second Opinion Form for teleconsults


This article is part of the Dry Eye Hub. Please also read Basics of Dry Eye, Dry Eye Second Opinion and Dry Eye: A Chronic Disease. Why Vision Becomes Blurred After Reading or Screen Use, and Why Are Your Dry Eye Drops Not Working may also help you understand your problem better.

You may also want to read this article written by Dr Bhartiya for NDTV online. And listen to her talk about dry eyes here.


Treatment: A Layered Approach

Dry eye treatment is not one-size-fits-all. It is matched to disease type, severity, and the dominant mechanism driving symptoms.

Step 1: Environmental and Behavioural Changes

Reduce screen time or use the 20-20-20 rule — every 20 minutes, look at something 20 feet away for 20 seconds. Increase blink frequency consciously. Use a humidifier in air-conditioned environments. Wear wraparound glasses in wind and dry air.

Step 2: Lid Hygiene and Warm Compresses

Warm compresses applied for 10 minutes daily soften meibomian secretions and improve gland expressibility. Lid massage after warming clears blocked glands. Lid scrubs with baby shampoo or commercially prepared wipes reduce bacterial load on the lid margin.

Consistency matters more than intensity. Daily lid hygiene over months produces measurable improvement in tear film quality.

Step 3: Lubricating Eye Drops

Not all lubricants are equivalent. Drops containing carboxymethylcellulose, sodium hyaluronate, or polyethylene glycol provide longer contact time. Preservative-free formulations are essential for patients using drops more than four times daily — preservatives accelerate the surface damage they are meant to relieve.

Gel formulations and ointments provide longer relief but blur vision temporarily and are best used at night.

Step 4: Omega-3 Fatty Acid Supplementation

Omega-3 supplements — particularly EPA and DHA from fish oil or re-esterified triglyceride formulations — improve meibomian secretion quality and reduce ocular surface inflammation. The DREAM study showed that high-dose omega-3 did not significantly outperform olive oil placebo, but clinical practice and other evidence support a role for supplementation in evaporative dry eye.

A daily dose of 2000 to 3000 mg EPA+DHA for at least three months is typically recommended.

Step 5: Anti-Inflammatory Therapy

When inflammation is driving symptoms, lubricants alone are insufficient. Cyclosporine eye drops (0.05% or 0.1%) reduce T-cell mediated inflammation on the ocular surface and restore goblet cell density over three to six months of use. They are not a quick fix — patients must be counselled on the time course.

Lifitegrast 5% is an integrin antagonist that blocks the LFA-1 to ICAM-1 interaction driving ocular surface inflammation. It offers symptom relief somewhat faster than cyclosporine.

Short-term topical corticosteroids are used to rapidly break the inflammatory cycle, particularly at disease onset or during flares. They are not for long-term use.

Please read Dry Eye Not Improving With Artificial Tears to understand the relationship between dry eyes and inflammation.

Step 6: Procedural Treatments

Intense Pulsed Light (IPL) therapy targets abnormal blood vessels on the lid margin that drive meibomian gland inflammation. It also applies heat that melts obstructed meibum. Multiple sessions spaced three to four weeks apart produce sustained improvement in many patients with moderate to severe MGD.

Thermal pulsation devices (LipiFlow) deliver controlled heat and pressure to the inner eyelid to express inspissated meibum. The effect can last six to twelve months and is repeatable.

Punctal plugs block the drainage of tears from the ocular surface. They are appropriate for aqueous deficient dry eye when lubrication alone is inadequate. Dissolvable collagen plugs are trialled before permanent silicone plugs are inserted.

TreatmentBest ForTime to Effect
Preservative-free lubricantsAll types, daily useImmediate symptom relief
Lid hygiene + warm compressesEvaporative / MGD4 to 8 weeks of daily use
Omega-3 supplementationEvaporative / MGD8 to 12 weeks
Cyclosporine dropsInflammatory DED3 to 6 months
Lifitegrast dropsInflammatory DED2 to 4 weeks for symptoms
IPL therapyModerate to severe MGDAfter 3 to 4 sessions
Punctal plugsAqueous deficient DEDDays to weeks

Monitoring Dry Eye Over Time

Dry eye is managed, not cured. Follow-up visits every three to six months allow the specialist to assess treatment response, adjust the regimen, and monitor for corneal surface deterioration.

Objective tests — TBUT, osmolarity, staining scores — are more reliable than symptoms alone. Patients often adapt to chronic discomfort and underreport severity. Imaging guides clinical decisions even when symptoms appear stable.

Meibomian gland dropout is irreversible. Preventing further loss is the priority once significant atrophy is identified.

Dry Eye and Systemic Disease

Dry eye is frequently a signal of systemic disease. Sjogren’s syndrome, rheumatoid arthritis, lupus, thyroid eye disease, and graft-versus-host disease all affect the ocular surface. Patients with unexplained severe dry eye — particularly younger women — should be evaluated for autoimmune conditions.

Conversely, patients already diagnosed with these conditions should have formal ocular surface assessments. Dry eye in this context needs co-management with the treating physician.


When to See a Glaucoma and Ocular Surface Specialist

Many patients with dry eye also have glaucoma or glaucoma suspect status. Glaucoma drops — particularly those with preservatives — are a significant cause of ocular surface disease. The benzalkonium chloride (BAK) in most preserved glaucoma drops is toxic to goblet cells and the corneal epithelium.

If you use glaucoma drops and have dry eye symptoms, your specialist needs to review both conditions together. Switching to preservative-free formulations or fixed-combination drops can reduce surface toxicity without compromising IOP control.

A specialist with expertise in both conditions can optimise your glaucoma management while actively protecting the ocular surface.

Known for her structured approach to glaucoma risk assessment and progression analysis, Dr Shibal Bhartiya provides trusted second opinions for patients seeking clarity before major treatment decisions. Both, in person, and online.


Frequently Asked Questions

Can dry eye disease be cured?

There is no permanent cure for most forms of dry eye disease. However, it can be very well controlled with the right treatment strategy. Many patients achieve significant symptom relief and stable ocular surface health with long-term management.

Are lubricating drops enough to treat dry eye?

For mild disease, lubricants provide adequate relief. For moderate to severe dry eye — or evaporative disease driven by meibomian gland dysfunction — drops manage symptoms but do not address the underlying cause. Lid hygiene, anti-inflammatory therapy, and sometimes procedural treatment are needed.

How do I know if my dry eye is getting worse?

Worsening symptoms, increased frequency of drop use, morning grittiness, light sensitivity, and fluctuating vision are all signs of progression. Objective worsening on TBUT, staining, or osmolarity testing confirms it. Do not wait for significant discomfort before seeking review.

Can diet help with dry eye?

Yes. Omega-3 fatty acids from oily fish, flaxseed, and walnuts support meibomian gland secretion quality. Adequate hydration matters. Foods high in omega-6 fatty acids and processed vegetable oils may worsen inflammation. A Mediterranean-style diet is broadly supportive of ocular surface health.

Is dry eye related to screen use?

Yes. Screen use reduces spontaneous blink rate from a normal 15 to 17 blinks per minute to as few as 3 to 5 blinks per minute. Reduced blinking causes tear film instability and accelerates evaporation. Deliberate blinking exercises and regular screen breaks are first-line recommendations for screen-related dry eye.

Can I wear contact lenses if I have dry eye?

Some patients with well-managed mild dry eye can wear contacts with modifications — daily disposable lenses, lubricating drops compatible with contact wear, and reduced wearing time. Patients with moderate to severe dry eye are advised to avoid contact lenses until surface health is restored. Scleral lenses are a specialist option for severe cases.

Read more here.

Does menopause cause dry eye?

Yes. Oestrogen and androgen deficiency after menopause reduces both aqueous and meibomian secretion. Dry eye prevalence in post-menopausal women is significantly higher than in age-matched men. Hormone replacement therapy has a complex relationship with dry eye — some studies show benefit, others do not. Ocular surface assessment after menopause is advisable.


Book a Dry Eye Assessment in Gurgaon

Dry eye responds best to early, structured management. A thorough ocular surface assessment — including meibography, osmolarity, and staining — identifies the cause and guides a treatment plan that works long-term.

If you are using lubricating drops daily and still struggling, the underlying mechanism has not yet been addressed. A specialist review changes that.

Drawing on more than 20 years of experience in glaucoma and ocular surface disease, Dr Shibal Bhartiya specialises in evaluating complex cases, difficult diagnoses, and patients seeking an expert second opinion.

Book an Appointment:

📍 Gurgaon 📞 +91 88826 38735 | 🌐 Contact Us | Second Opinion Form for teleconsults

At our Dry Eye Clinic & Treatment Centre in Gurgaon, persistent dry eye is evaluated through The C.L.E.A.R.™ Framework — Comprehensive Etiology Sub-Classification, Lipid & Meibomian Gland Mapping, Environmental & Systemic Triaging, Advanced Inflammation Profiling, and Root-Cause Targeted Rehabilitation. Based on meibography, NIBUT and osmolarity, it maps your exact subtype to design targeted therapy beyond artificial tears, including IPL / thermal pulsation when indicated. Learn more about our dry eye clinic →


About the Author

This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.

She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.

As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.

Access her work on Pubmed, Google Scholar, ResearchGate and ORCID.

Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care

www.drshibalbhartiya.com
 +91 88826 38735

1500+ Five Star Patient Reviews Google Business Profile

Upload your reports for a structured review.

If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation

Read More

Basics of Dry Eye

Dry Eye Second Opinion

Dry Eye: A Chronic Disease

Why Do Women Get Dry Eye More Often?

Menopause and Dry Eye

Dry Eyes: Natural Remedies

Dry Eyes: Tips to Soothe Sore Eyes

Why Dry Eye Is Worse in Air Conditioning and on Flights

Why Vision Becomes Blurred After Reading or Screen Use

Screen Fatigue

Why Your Eyes Water Constantly

Omega-3 and Dry Eye

Why Are Your Dry Eye Drops Not Working

Autologous Serum Eye Drops for Severe Dry Eye

Glaucoma and Dry Eye

Dry Eye Second Opinion Framework

Do I Need to Treat Dry Eye Before Cataract Surgery?

Why Do Women Get Dry Eye More Often?

Should We Wash Eyes

Ocular GVHD

Ocular GVHD or GVHD of the eye is an immune mediated inflammation that may affect patients who have had bone marrow transplants.